Breastfeeding Support for Families Impacted by OUD

About this training: 

This program will describe the impact of Opioid Use Disorder on mothers and infants and practical ways to proactively support people in recovery who choose to breastfeed.  Guidance on preparing parents/guardians to care for infants diagnosed with Neonatal Abstinence Syndrome will also be provided.

Presenter: Dr. Roschanak Mossabeb, MD, Section Chief if Neonatology and Attending Physician, Temply University

Attendning Physician, St. Christopher's Hospital for Children

Target Audience:  Lactation Consultants who provide care for families impacted by Opioid Use Disorder
Learning Objectives:  After attending this program, participants will be able to:

1. Discuss the impact of OUD on mothers and infants.
2. Review the elements of a compassionate approach and treatment options for perinatal OUD.
3. Describe the benefits and barriers to breastfeeding opioid-exposed infants.
4. Discuss how to prepare parents/guardians for care of infants diagnosed with neonatal abstinence syndrome.

Cost:  There is no fee for this program, including continuing education. Advance application and registration is required.

Registration: https://www.eventbrite.com/e/390456294287

ACCREDITATION STATEMENT

Disclosure to Receive Contact Hours
1.5 instructional hours in topics on the IBLCE Exam Blueprint. 1.5 L CERPs. Attendees may earn a maximum of 1.5 contact hours for completion of this activity. To receive a certificate of completion, attendees must:

1. Be registered as a participant.
2. Be seated in the room no later than 10 minutes after the training has started and until the scheduled ending time.
3. Complete the post training evaluation.

Deadline to claim contact hours: November 8, 2022
FACULTY DISCLOSURE STATEMENT  
Speakers at continuing education activities are required to disclose to the audience, any relevant commercial interest (which is any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients).  Any conflicts of interest must be resolved prior to the presentation and announced to the audience. The intent of this disclosure is to allow participants to form their own judgments about the educational content of this activity and determine whether the speaker’s commercial interests influenced the presentation. In addition, speakers are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation.
FACULTY DISCOSURES: Roschanak Mossabeb, MD, has no commercial relationships to disclose.
FUNDING ACKNOWLEDGEMENT: Supported by funding from Philadelphia Department of Public Health.